1295583-21-9

Basic information

• Product Name: methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate
• Synonyms: methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate
• CAS NO: 1295583-21-9
• Molecular Weight: 166.18
• Mol File: 1295583-21-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate(1295583-21-9)
• EPA Substance Registry System: methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate(1295583-21-9)

Safety Data

• Hazardous Substances Data: 1295583-21-9(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 689251-97-6 (E)-3-(1-methyl-1H-pyrazol-4-yl)acrylic acid 
• 5927-18-4 trimethyl phosphonoacetate 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 

Downstream Products

• 224776-32-3 methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate 
• 1380427-95-1 2-((3-methoxy-4-(3-(trifluoromethyl)phenoxy)benzyl)thio)-5-((1-methyl-1H-pyrazol-4-yl)methyl)pyrimidin-4(1H)-one 
• 1380427-97-3 C₂HF₃O₂*C₂₅H₂₃F₃N₄O₃S 
• 1380428-00-1 5-[2-({5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-oxo-1,4-dihydro-2-pyrimidinyl}thio)ethyl]-2-{[3-(trifluoromethyl)phenyl]oxy}benzonitrile 
• 1380428-06-7 2-((4-(4-chloro-3-(trifluoromethyl)phenoxy)phenethyl)thio)-5-((1-methyl-1H-pyrazol-4-yl)methyl)pyrimidin-4(1H)-one 
• 1380428-07-8 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]thio}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-20-5 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(4-{[4-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]oxy}-4(1H)-pyrimidinone 
• 1380426-85-6 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-36-3 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-{[2-(4-{[6-(trifluoromethyl)-3-pyridinyl]oxy}phenyl)ethyl]oxy}-4(1H)-pyrimidinone 
• 1380428-49-8 2-[(2-{4-[(3-chloro-4-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-52-3 2-[(2-{4-[(4-chloro-3-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-56-7 2-[(2-{4-[(3-fluoro-4-methylphenyl)oxy]phenyl}ethyl)oxy]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380426-88-9 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-1-methyl-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-59-0 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-[(2-{4-[(6-methyl-2-pyridinyl)oxy]phenyl}ethyl)oxy]-4(1H)-pyrimidinone 

Relevant articles and documents

Synthesis of 1-hetaryl-2,2-difluorocyclopropane-derived building blocks: The case of pyrazoles

An approach to 1-hetaryl-2,2-difluorocyclopropane building blocks compatible with the current criteria of lead-oriented synthesis was developed and implemented for the case of 3-, 4- and 5-subsituted pyrazole derivatives. The method implied 6–9 synthetic steps, including difluorocyclopropanation with the TMSCF3–NaI system as the key transformation, and provided the title compounds on up to gram scale. The scope of the procedures towards substitution in the pyrazole ring and typical functional groups (i.e. COOH, NH2, CH2NH2, CH2OH) was established. The results obtained allowed formulation of preliminary guidelines for the synthetic feasibility of various functionalized 1-hetaryl-2,2-difluorocyclopropanes. 2018 Elsevier Ltd. All rights reserved.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

HISTONE DEACETYLASE INHIBITORS

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).